Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OptimizeRx Corporation (OPRX)
NASDAQ:OPRX
Holding OPRX?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.27Last Year’s EPS
0.26Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2018
|% Change Since: -21.95%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Neutral
The earnings call reflected a mixed sentiment with strong year-over-year revenue growth and significant improvements in gross margin and EBITDA. However, the company faced challenges with a revenue shortfall, increased net loss, and a goodwill impairment charge. Positive developments in client engagement, DAAP integration, and pipeline growth were highlighted, but the transition in the DTC business posed challenges.Company Guidance
During OptimizeRx's Q3 2024 earnings call, the company updated its guidance, projecting annual revenue for 2024 to be between $88 million and $92 million, with adjusted EBITDA expected to range from $8 million to $10 million. The quarter saw a 30% year-over-year revenue growth, reaching $21.3 million. However, this fell short of expectations due to a shift in the Direct-to-Consumer (DTC) business towards a self-service model, which impacted managed services revenue. Despite this, the legacy Healthcare Provider (HCP) business performed well, supporting cash flow and operating efficiencies. The company highlighted significant growth in its micro neighborhood targeting and noted progress in cross-selling and upselling efforts, leading to expectations of substantial revenue from major clients in 2025. OptimizeRx remains optimistic about its strategic position within the evolving privacy regulation landscape and continues to expand its point-of-care network and AI solutions.Year-Over-Year Revenue Growth
The company reported a year-over-year top line revenue growth of 30%, reaching $21.3 million.
Gross Margin Improvement
Gross margin for the quarter improved significantly to 60% compared to the previous year.
Adjusted EBITDA Performance
Adjusted EBITDA came in at $2.7 million for Q3 2024, compared to $0.9 million in Q3 2023, highlighting improving margins and cost-cutting initiatives.
Client Engagement and Pipeline Growth
A notable increase in customer engagements and pipeline growth, with a top 3 pharmaceutical manufacturer adopting the company's solutions.
DAAP and AI Integration
DAAP is now integrated with the company's omnichannel network, driving significant AI-related opportunities and capturing market share.
---
OPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $6.15 | $4.06 | -33.98% |
| Aug 08, 2024 | $8.85 | $8.38 | -5.31% |
| May 14, 2024 | $10.48 | $13.17 | +25.67% |
| Apr 16, 2024 | $10.32 | $9.96 | -3.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does OptimizeRx Corporation (OPRX) report earnings?
OptimizeRx Corporation (OPRX) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is OptimizeRx Corporation (OPRX) earnings time?
OptimizeRx Corporation (OPRX) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OPRX EPS forecast?
OPRX EPS forecast for the fiscal quarter 2024 (Q4) is 0.27.
---